UNSPSC 51142024: Dronabinol

This classification denotes an antiemetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7J8897W37S. European Medicines Agency schedules Dronabinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06407MIG. Dronabinol generally arises in the molecular formula C21H30O2.

UNSPSC 51142024 Dronabinol is a Commodity code that covers pharmaceutical active ingredients and finished pharmaceutical products purchased by state and local health agencies, with recent state and local activity showing dronabinol itself appearing only incidentally in broader pharmaceutical procurement contexts. The recent opportunities in the code's footprint actually span naloxone and drug deactivation systems, generic multi-source pharmaceuticals, and therapeutic pharmacy direct-contracting initiatives. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multi-state cooperative purchasing alliances (MMCAP, administered by the Minnesota Department of Administration). These solicitations reflect state and local governments' focus on opioid-response medications, cost-effective generic drug procurement, and value-based pharmaceutical distribution models rather than specialty pharmaceutical ingredients alone.

Recent activity centers in Florida, Texas, and Minnesota through MMCAP's multi-state footprint, including Oregon participation. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) seeking vendor capability information on direct-to-manufacturer prescription programs for state pharmacy benefit plans; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across Minnesota, Oregon, and participating jurisdictions, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 5 percent each on administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. The code shows limited direct activity tied specifically to dronabinol as a named product; recent opportunities suggest broader pharmaceutical procurement categories dominate state and local purchasing under this classification.